Why the study?
Does CV-3317 inhibit ACE activity and angiotensin I-induced pressor responses more potently than captopril in preclinical models?
Does CV-3317 inhibit ACE activity and angiotensin I-induced pressor responses more potently than captopril in preclinical models?
CV-3317 is a potent, long-acting non-sulfhydryl ACE inhibitor that effectively inhibits vascular ACE in spontaneously hypertensive rats, suggesting its potential utility as an antihypertensive agent.
No takes yet. Share an insight, caveat, or question.
Supports CV-3317 development as antihypertensive candidate; leaves open translation of potency to human efficacy and safety.
Inada et al. (1986) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: